APA

Nigmatullina R. R., Kirillova V. V., Jourjikiya R. K., Mukhamedyarov M. A., Kudrin V. S., Klodt P. M. & Palotás A. (20090924). Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. : Cardiology.

Chicago

Nigmatullina Razina R, Kirillova Venera V, Jourjikiya Roen K, Mukhamedyarov Marat A, Kudrin Vladimir S, Klodt Petr M and Palotás András. 20090924. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. : Cardiology.

Harvard

Nigmatullina R. R., Kirillova V. V., Jourjikiya R. K., Mukhamedyarov M. A., Kudrin V. S., Klodt P. M. and Palotás A. (20090924). Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. : Cardiology.

MLA

Nigmatullina Razina R, Kirillova Venera V, Jourjikiya Roen K, Mukhamedyarov Marat A, Kudrin Vladimir S, Klodt Petr M and Palotás András. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. : Cardiology. 20090924.